Segment and Enterprise Wide Disclosures

12 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Segment and Enterprise Wide Disclosures

Note 17. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. International sales (sales outside the U.S. and primarily in Europe) accounted for 18%, 16% and 14% of total revenue during the fiscal years ended March 31, 2021, 2020 and 2019, respectively. As of March 31, 2021 and 2020, most of the Company’s long-lived assets are located in the U.S. except for $56.4 million and $46.7 million as of March 31, 2021 and 2020, respectively, which are located primarily in Germany.